Wockhardt’s breakthrough respiratory drug Zaynich moves a step closer to market as the US FDA accepts it for review, boosting approval odds and keeping the company on track for its mid-2026 launch target. Equity analyst Vishal Manchanda says the priority revi…
US FDA review boosts odds for Wockhardt’s NCE success story: Vishal Manchanda
